Illumina Oncology - Does finding a rare mutation accomplish anything?
Rachel E. Sanborn, MD, presents the journey of a patient diagnosed with atypical carcinoid with brain metastases who benefited from the detection of a RET fusion by comprehensive genomic profiling.
Rachel E. Sanborn, MD is the medical director of the Thoracic Oncology and Phase I Clinical Trials Programs at the Earle A. Chiles Research Institute at Providence Cancer Institute.
Learn about liquid biopsy CGP: • Illumina Oncology – Liquid biopsy NGS...
Learn about when to test for NTRK fusions: • Illumina Oncology - Testing for 𝘕𝘛𝘙𝘒 ...
Subscribe to the Illumina video channel http://www.youtube.com/subscription_c...
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
View customer spotlight videos
• Illumina Customer Testimonials
View Illumina webinars
• Webinars
View Illumina support videos
• Illumina Support
Facebook: / illuminainc
LinkedIn: / illumina
Instagram: / illuminainc
Twitter: / illumina
